Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06296823 · ClinicalTrials.gov registry record · NA
Biomarkers for Peripheral Circadian Clocks in Humans
A NA study of Circadian Rhythms, sponsored by University of Colorado, Boulder.
- Recruiting
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT06296823: Recruiting NA study of Circadian Rhythms, sponsored by University of Colorado, Boulder.
NCT06296823 is a NA study of Circadian Rhythms that is actively recruiting participants, run by University of Colorado, Boulder. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06296823, a NA study of Circadian Rhythms, is actively recruiting participants, sponsored by University of Colorado, Boulder.
- RECRUITING
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to improve our understanding of peripheral circadian rhythms in humans. Circadian clocks are present in most tissues of the body with importance for optimal physiological function, health, and behavior. This project will utilize simulated jetlag protocols to systematically test novel hypotheses about the regulation of peripheral circadian rhythms in humans. Specifically, we will examine how changes in the time of when we are exposed to light and the timing of when we eat impacts proteins in the blood and saliva that represent rhythms from clocks in the brain (e.g., rhythms of the hormones melatonin and cortisol coordinated by the brain) and rhythms from clocks in body tissues (e.g., proteins made by immune and bone cells, and cells in the stomach and liver). We also aim to discover new blood-based biomarkers of peripheral rhythms in humans. We anticipate our findings will be the first step in developing novel circadian based treatments for aligning peripheral clocks under conditions such as jetlag, and for developing novel circadian biomarkers that will advance our scientific understanding of circadian rhythms.
Primary Outcome
Appetitive hormone-promotes satiety
Conditions Studied
Interventions
- BEHAVIORAL Simulated jetlag protocol
Study Locations (1)
Colorado
- Sleep and Chronobiology Laboratory - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT06296823 shows while recruiting
NCT06296823 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Circadian Rhythms appearing as the primary indexed condition, and to 1 intervention - of which Simulated jetlag protocol is the first listed.
NCT06296823 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06296823 about?
NCT06296823 is a clinical study titled "Biomarkers for Peripheral Circadian Clocks in Humans". The purpose of this project is to improve our understanding of peripheral circadian rhythms in humans. Circadian clocks are present in most tissues of the body with importance for optimal physiological function, health, and behavior. This project will utilize simulated jetlag protocols to systematic...
What is the current status of trial NCT06296823?
This trial is currently recruiting. It is a NA study. The enrollment target is 14 participants. The study started on 2023-09-01. Estimated completion is 2027-08-31.
What conditions does trial NCT06296823 study?
This clinical trial studies the following conditions: Circadian Rhythms.
What interventions are being tested in trial NCT06296823?
The interventions under investigation include: Simulated jetlag protocol (BEHAVIORAL).
Who is sponsoring clinical trial NCT06296823?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06296823 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Circadian Rhythms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06296823's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy